Jan 29, 2021 2:45pm EST Rigel Awarded $16.5 Million from U.S. Department of Defense for Phase 3 Clinical Trial of Fostamatinib in COVID-19 Patients
Dec 04, 2020 7:30am EST Rigel Announces Two Posters Highlighting TAVALISSE at the 62nd ASH Annual Meeting & Exposition
Nov 23, 2020 7:30am EST Rigel and Medison Announce Health Canada Approval of TAVALISSE®, an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia
Nov 17, 2020 7:30am EST Rigel Finalizes the Study Design of its Ongoing Phase 3 Clinical Trial of Fostamatinib in Warm Autoimmune Hemolytic Anemia
Nov 05, 2020 4:01pm EST Rigel Reports Third Quarter 2020 Financial Results and Provides Business Update
Oct 29, 2020 7:30am EDT Rigel Announces Conference Call and Webcast to Report Third Quarter 2020 Financial Results and Business Update
Oct 09, 2020 7:30am EDT Rigel Announces First Patients Enrolled in NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova
